venclyxto 10 mg filmtabletten
abbvie ag - venetoclaxum - filmtabletten - venetoclaxum 10 mg, copovidonum k 28, polysorbatum 80, silica colloidalis anhydrica, calcii phosphas, natrii stearylis fumaras corresp. natrium 0.03 mg, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (flavum), pro compresso obducto. - chronisch lymphatische leukämie (cll), akute myeloische leukämie (aml) - synthetika
venclyxto 50 mg filmtabletten
abbvie ag - venetoclaxum - filmtabletten - venetoclaxum 50 mg, copovidonum k 28, polysorbatum 80, silica colloidalis anhydrica, calcii phosphas, natrii stearylis fumaras corresp. natrium 0.15 mg, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro compresso obducto. - chronisch lymphatische leukämie (cll), akute myeloische leukämie (aml) - synthetika
venclyxto 100 mg filmtabletten
abbvie ag - venetoclaxum - filmtabletten - venetoclaxum 100 mg, copovidonum k 28, polysorbatum 80, silica colloidalis anhydrica, calcii phosphas, natrii stearylis fumaras corresp. natrium 0.31 mg, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (flavum), pro compresso obducto. - chronisch lymphatische leukämie (cll), akute myeloische leukämie (aml) - synthetika
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukämie, lymphozytär, chronisch, b-zell - antineoplastische mittel - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
ventolair 100 µg easi-breathe druckgasinhalation, lösung
teva gmbh - beclometasondipropionat (ph.eur.) - druckgasinhalation, lösung - beclometasondipropionat (ph.eur.) 0.1mg
ventolair mite 50 µg easi-breathe druckgasinhalation, lösung
teva gmbh - beclometasondipropionat (ph.eur.) - druckgasinhalation, lösung - beclometasondipropionat (ph.eur.) 0.05mg
ventolair 100 µg autohaler druckgasinhalation, lösung
teva gmbh - beclometasondipropionat (ph.eur.) - druckgasinhalation, lösung - beclometasondipropionat (ph.eur.) 0.1mg
ventolair 250 µg easi-breathe druckgasinhalation, lösung
teva gmbh - beclometasondipropionat (ph.eur.) - druckgasinhalation, lösung - beclometasondipropionat (ph.eur.) 0.25mg
ventolair 250 µg dosieraerosol druckgasinhalation, lösung
teva gmbh - beclometasondipropionat (ph.eur.) - druckgasinhalation, lösung - beclometasondipropionat (ph.eur.) 0.25mg
ventolair 100 µg dosieraerosol druckgasinhalation, lösung
teva gmbh - beclometasondipropionat (ph.eur.) - druckgasinhalation, lösung - beclometasondipropionat (ph.eur.) 0.1mg